Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study |
| |
Authors: | Rutkowski S De Vleeschouwer S Kaempgen E Wolff J E A Kühl J Demaerel P Warmuth-Metz M Flamen P Van Calenbergh F Plets C Sörensen N Opitz A Van Gool S W |
| |
Affiliation: | Department of Pediatric Oncology, Children's Hospital, University of Wuerzburg, Josef-Schneider-Str. 2, D-97080 Wuerzburg, Germany. |
| |
Abstract: | Patients with relapsed malignant glioma have a poor prognosis. We developed a strategy of vaccination using autologous mature dendritic cells loaded with autologous tumour homogenate. In total, 12 patients with a median age of 36 years (range: 11-78) were treated. All had relapsing malignant glioma. After surgery, vaccines were given at weeks 1 and 3, and later every 4 weeks. A median of 5 (range: 2-7) vaccines was given. There were no serious adverse events except in one patient with gross residual tumour prior to vaccination, who repetitively developed vaccine-related peritumoral oedema. Minor toxicities were recorded in four out of 12 patients. In six patients with postoperative residual tumour, vaccination induced one stable disease during 8 weeks, and one partial response. Two of six patients with complete resection are in CCR for 3 years. Tumour vaccination for patients with relapsed malignant glioma is feasible and likely beneficial for patients with minimal residual tumour burden. |
| |
Keywords: | glioma immunotherapy tumour vaccination dendritic cells adjuvant therapy |
本文献已被 PubMed 等数据库收录! |
|